Business
PMx Promotional Partner Contract Enhancement
PMx Promotional Partner Contract Enhancement.
About this update from Diaceutics Plc
[{"type":"text","content":"\n\nDiaceutics PMx Promotional Partner Contract Enhancement\n \nTransition to new PMx customer and enhanced commercial terms agreed post the license of US rights to BIZENGRI® (zenocutuzumab - zbco) to Partner Therapeutics Inc.\n \nExtended multi-year PMx promotional partnership to be worth up to £11.5m\n \nNew York, Belfast and London, 26 March 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces that it has agreed contractual terms with Partner Therapeutics, Inc. (Partner Therapeutics), the new US license holder for the oncology precision medicine BIZENGRI® (zenocutuzumab - zbco). Partner Therapeutics will continue to deploy the PMx commercialisation solutions previously contracted with the previous US license holder. The Partner Therapeutics PMx contract supersedes the contract previously announced on 19 August 2024.\n \nRyan Keeling, Diaceutics' Chief Executive Officer, commented: \"We are very excited to be working with Partner Therapeutics as they commercialise this novel and important therapy for patients with unmet needs. Our platform will enable Partner Therapeutics to identify and ensure patients get the opportunity to be treated with the optimal oncology therapy as fast as possible. The team at Partner Therapeutics recognises the need for an innovative commercial model and the potential for our PMx solution to deliver significant value as they bring BIZENGRI® to market.\"\n \nPMx is a commercialisation service designed to combine all of Diaceutics' unique solutions to ensure patients are identified, based on their unique genomic profile, and offered the optimal treatment for their condition as fast as possible. With Diaceutics' best in class daily Signal product at its core, Diaceutics will provide all of the DXRX platform services including patient identification, patient recruitment, diagnostic test adoption & optimisation and physician engagement & education.\n \nPMx represents a novel commercialisation solution which allows pharma and biotech companies to launch precision medicines in a more lean and agile way, whilst accelerating the adoption curve and maximising patients on therapy - an approach that Diaceutics believes is revolutionary for the precision medicine marke...